Cumberland Pharmaceuticals Inc. last reported quarterly results on Aug 4, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $8.8 million (-18.8% year over year) and diluted EPS of -$0.29. It usually reports 35–62 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 3, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Nov 4, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–62 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
9
-18.8%
|
-4
-477.3%
|
-0.29
-480.0%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
—
|
—
|
|
Mar 3, 2026
62 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
14
+31.1%
|
-1
+25.8%
|
-0.09
+35.7%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
8
-8.7%
|
-2
-25.7%
|
-0.13
-18.2%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
11
+10.0%
|
-1
+31.8%
|
-0.05
+37.5%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
12
+37.8%
|
1
+164.6%
|
0.08
+157.1%
|
|
Mar 4, 2025
63 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
10
+11.6%
|
-2
+69.8%
|
-0.14
+68.2%
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
9
-9.9%
|
-2
-47.2%
|
-0.11
-49.7%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CPIX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TN
- Headquarters
- Nashville,, TN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1087294
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.